# GCC Montelukast API Market

> GCC Montelukast API Market Research Report By Application (Asthma, Allergic Rhinitis, Bronchospasm, Urticaria, Others) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 10.55%
- **2024:** $ 38.88 Million
- **2025:** $ 42.99 Million
- **2035:** $ 117.25 Million
- **Key Players:** Merck & Co (US), Teva Pharmaceutical Industries (IL), Mylan N.V. (US), Sandoz (CH), Aurobindo Pharma (IN), Cipla (IN), Hikma Pharmaceuticals (GB), Zydus Cadila (IN), Sun Pharmaceutical Industries (IN)

**Report ID:** MRFR/HC/51333-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** August 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/gcc-montelukast-api-market-53094

---

## Market Summary

## **GCC Montelukast API Market Overview:**

As per MRFR analysis, the GCC Montelukast API Market Size was estimated at 27 (USD Million) in 2023. The GCC Montelukast API Market Industry is expected to grow from 30.3(USD Million) in 2024 to 99 (USD Million) by 2035. The GCC Montelukast API Market CAGR (growth rate) is expected to be around 11.364% during the forecast period (2025 - 2035).

### **Key GCC Montelukast API Market Trends Highlighted**

The GCC Montelukast API market is experiencing an upward trend, which is primarily due to the rising prevalence of respiratory diseases, particularly asthma and allergic rhinitis, which are prevalent in the region. This increase in respiratory issues is associated with environmental factors, such as the urbanization and air pollution that are prevalent in numerous GCC countries.

Key market drivers are government initiatives that prioritize the importance of effective treatment options, with the objective of enhancing public health and alleviating the burden of these diseases. For example, the demand and awareness of medications such as Montelukast are being increased by initiatives that concentrate on asthma management in schools and communities. Exploring opportunities within the GCC Montelukast API market is being facilitated by the region's strategic location, which facilitates easy export and import activities. By utilizing a variety of Free Trade Agreements (FTAs), manufacturers can gain access to potentially larger markets.

Furthermore, there is an increasing trend toward the production of pharmaceuticals locally, which is facilitated by national policies that promote industrial development. This enables companies to more effectively access the domestic market. The GCC's expansion of healthcare facilities and services also presents an opportunity for increased consumption of Montelukast, which is indicative of a trend toward more accessible healthcare. In recent years, there has been a growing trend of collaboration between the public and private sectors to improve the capabilities of pharmaceutical research and development.

Regulatory bodies in the GCC are gradually simplifying the approval process for new medications, which will facilitate the entry of Montelukast APIs into the market. Additionally, regulatory reforms are fostering an increased emphasis on bioequivalence and quality assurance to guarantee the safety and efficacy of medications. These trends suggest that the Montelukast API market in the GCC will become more competitive and robust, which is indicative of the region's dedication to enhancing healthcare outcomes.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **GCC Montelukast API Market Drivers**

### Rising Asthma Prevalence in GCC Countries

The increasing prevalence of asthma in the Gulf Cooperation Council (GCC) region is a significant driver for the GCC Montelukast API Market Industry. According to the World Health Organization (WHO), asthma affects approximately 300 million individuals globally, with elevated rates in the Middle East and North Africa region. Specifically, the Qatar National Health Strategy 2018-2022 reports that asthma prevalence in younger populations can reach as high as 15% in some GCC states. This growing patient pool propels the demand for Montelukast, a medication widely prescribed to manage asthma symptoms effectively.

Furthermore, the Gulf Research Centre indicates that public health campaigns in GCC countries are increasingly focused on respiratory diseases, fostering an environment conducive to the growth of the Montelukast API market. As awareness increases and more patients seek treatment, the market is expected to expand significantly.

### Government Initiatives to Enhance Healthcare Accessibility

The GCC governments are intensifying efforts to improve healthcare accessibility, which is driving the GCC Montelukast API Market Industry. For instance, the Saudi Vision 2030 initiative aims to enhance health services, ensuring all citizens have adequate access to treatments for chronic conditions, including asthma. Public health reforms in countries like the United Arab Emirates (UAE) focus on integrating advanced medical treatments into the public health system. According to the Ministry of Health and Prevention in the UAE, more than 30% of common respiratory disorders are treated with medications like Montelukast.

Consequently, as healthcare infrastructure strengthens, availability and prescription rates of Montelukast are expected to rise, contributing to market growth.

### Increased Focus on Chronic Respiratory Diseases Research

An increasing emphasis on Research and Development (R&D) for chronic respiratory diseases is propelling the GCC Montelukast API Market Industry. Institutions such as the Qatar Biomedical Research Institute are focused on lifting the level of research on respiratory illnesses, which has seen a significant boost in funding and collaboration. They report an expected 20% increase in R&D spending on respiratory diseases in the next five years.

This investment allows for innovations in treatment protocols and medications, which includes the potential development of advanced formulations of Montelukast.With more research backing the effectiveness of Montelukast, healthcare providers are more likely to recommend it as a first-line treatment, driving market growth forward.

## **GCC Montelukast API Market Segment Insights:**

### **Montelukast API Market Application Insights**

The GCC Montelukast API Market is showing significant potential within the Application segment, driven by a range of therapeutic needs across various respiratory and allergic conditions. The market reflects a substantial emphasis on managing asthma, a prevalent health issue in the Gulf Cooperation Council region, where rising pollution levels and lifestyle changes contribute to increasing cases of respiratory diseases. This aspect highlights the critical importance of effective treatments, making the asthma application a significant domain within this market. Similarly, allergic rhinitis is a common ailment affecting a large portion of the population, reinforced by climatic conditions that trigger allergies.

This drives demand for Montelukast as an effective option for alleviating symptoms. Bronchospasm presents another area where Montelukast is vital, often associated with chronic respiratory conditions, increasing the need for robust treatment options. Understanding the GCC's climatic challenges, it's essential to recognize how these conditions impact daily life and overall health, prompting a focus on effective management strategies. Urticaria, though less prevalent, adds another layer to the market landscape, as it requires reliable treatment solutions to enhance patient quality of life. Other applications within this segment cater to a broad spectrum of needs, indicating diverse market interests.

As the GCC market continues to grow, opportunities may arise from increasing awareness, healthcare investments, and the emergence of new therapeutic strategies related to Montelukast, highlighting the interconnectedness of healthcare and market growth in the region. Collectively, these insights provide a clear perspective on how different applications of Montelukast serve vital roles in addressing health challenges within the GCC, positioning the market for continued evolution and expansion driven by diverse patient needs and the region's unique environmental factors.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **GCC Montelukast API Market Key Players and Competitive Insights:**

The GCC Montelukast API Market is characterized by a dynamic competitive landscape shaped by various factors including regulatory frameworks, market demand, and the increasing prevalence of respiratory conditions. Montelukast, a leukotriene receptor antagonist widely utilized for the treatment of asthma and allergic rhinitis, is gaining traction across the Gulf Cooperation Council countries due to rising awareness about respiratory disorders and the growing adoption of preventive healthcare measures. The competitive environment in this market is influenced by the presence of both multinational corporations and emerging local players, which are focused on optimizing production capabilities and enhancing distribution networks.

Furthermore, the pipeline for innovative formulations and collaborations within the region adds another layer of complexity to this market, as companies strive for competitive advantage through product diversity and improved efficacy. Teva Pharmaceutical Industries has established a significant presence in the GCC Montelukast API Market, leveraging its global scale to penetrate local markets effectively. The company is recognized for its robust manufacturing capabilities and commitment to quality, which positions it favorably against competitors. Teva's strengths lie in its diverse portfolio of generic and specialty pharmaceuticals, allowing it to cater to varying patient needs across the region.

With a strong emphasis on research and development, Teva continuously seeks to enhance its product offerings, ensuring compliance with local regulatory requirements. Additionally, its strategic partnerships with local distributors facilitate improved access to its Montelukast products, enhancing visibility and market share in the GCC.Amgen, while primarily known for its biopharmaceutical innovations, is also making strides in the GCC Montelukast API Market by addressing respiratory health challenges within the region. The company's emphasis on research and development allows it to provide compelling therapies that enhance patient outcomes.

Amgen's strengths in the GCC stem from its strong branding and marketing strategies, which focus on building trusted relationships with healthcare professionals and stakeholders. Furthermore, the company's engagement in potential mergers and acquisitions within the strategic landscape of the GCC has allowed it to expand its footprint and diversify its product offerings. With a focus on delivering high-quality, patient-focused solutions, Amgen continues to solidify its position in the GCC Montelukast API Market, ensuring that it meets the evolving healthcare demands of the region.

### **Key Companies in the GCC Montelukast API Market Include:**

## **GCC Montelukast API Market Industry Developments**

Recent developments in the GCC Montelukast Active Pharmaceutical Ingredient (API) Market have shown significant growth, with key players like Teva Pharmaceutical Industries, Hikma Pharmaceuticals, and Merck expanding their operations. In September 2023, Hikma Pharmaceuticals secured approval for a new Montelukast formulation which is expected to increase market penetration in the GCC region. Meanwhile, Amgen and Lupin Pharmaceuticals are enhancing their presence through collaborations and partnerships aimed at improving accessibility to Montelukast in local markets.

In July 2023, Fresenius Kabi announced its plan to increase manufacturing capacity for Montelukast API, responding to rising demand.Over the past two years, the GCC market has witnessed steady growth, bolstered by the increasing prevalence of asthma and allergic rhinitis, driving demand for Montelukast. Additionally, in early 2022, Zydus Cadila announced a strategic partnership with local distributors to enhance its market share in GCC countries. However, no significant mergers and acquisitions involving the specified companies have been reported recently.

Overall, the market continues to evolve with strong contributions from various players, reflecting an optimistic outlook driven by healthcare reforms and regulatory support across the GCC.

## **GCC Montelukast API Market Segmentation Insights**

### **Montelukast API Market Application****Outlook**

## Market Drivers

### Growing Demand for Generic Medications

The montelukast api market is witnessing a surge in demand for generic medications, driven by the increasing cost of healthcare and the need for affordable treatment options. As patents for branded montelukast expire, generic versions are becoming more accessible to patients in the GCC. This shift is particularly relevant in a region where healthcare costs are a concern for many. The availability of generic montelukast is likely to enhance market penetration, as healthcare providers and patients alike seek cost-effective alternatives. Consequently, the montelukast api market is expected to expand as generic manufacturers enter the market, offering competitive pricing and contributing to overall market growth.

### Rising Awareness of Preventive Healthcare

There is a notable shift towards preventive healthcare in the GCC, which is significantly impacting the montelukast api market. As populations become more health-conscious, there is an increasing emphasis on early intervention and management of chronic conditions like asthma. This trend is reflected in the growing number of health awareness campaigns and educational programs that focus on respiratory health. Consequently, healthcare providers are more frequently prescribing montelukast as a preventive measure, which could lead to a substantial increase in its market share. The montelukast api market is likely to benefit from this proactive approach to health management, as patients seek effective solutions to prevent asthma attacks.

### Increasing Prevalence of Allergic Conditions

The montelukast api market is experiencing growth due to the rising prevalence of allergic conditions such as asthma and allergic rhinitis in the GCC region. Reports indicate that asthma affects approximately 10-15% of the population in some GCC countries, leading to a heightened demand for effective treatments. Montelukast, as a leukotriene receptor antagonist, plays a crucial role in managing these conditions. The increasing awareness of respiratory health and the need for preventive measures further drive the market. As healthcare providers emphasize the importance of managing allergies, the montelukast api market is likely to expand, catering to a growing patient base seeking relief from respiratory ailments.

### Government Initiatives for Healthcare Improvement

Government initiatives aimed at improving healthcare infrastructure in the GCC are positively influencing the montelukast api market. Investments in healthcare facilities and the promotion of essential medicines are part of broader strategies to enhance public health. For instance, the GCC governments have allocated substantial budgets for healthcare, with some countries increasing their healthcare spending by over 10% annually. This focus on healthcare improvement is expected to facilitate better access to montelukast and similar medications, thereby boosting the market. Additionally, public health campaigns aimed at educating citizens about respiratory diseases are likely to increase the demand for montelukast, further propelling market growth.

### Expansion of Pharmaceutical Manufacturing Capabilities

The montelukast api market is being positively influenced by the expansion of pharmaceutical manufacturing capabilities within the GCC. Several countries in the region are investing in advanced manufacturing technologies to produce high-quality active pharmaceutical ingredients (APIs). This development is crucial as it enhances the local production of montelukast, reducing dependency on imports. Reports suggest that the GCC pharmaceutical market is projected to grow at a CAGR of around 7% over the next few years. As local manufacturers ramp up production, the availability of montelukast is expected to increase, potentially lowering costs and improving access for patients, thereby stimulating market growth.

## Future Outlook

The [Montelukast API Market](https://www.marketresearchfuture.com/reports/montelukast-api-market-7886) is projected to grow at a 10.55% CAGR from 2025 to 2035, driven by increasing asthma prevalence and rising healthcare expenditure.

**New opportunities:**

- Expansion of online distribution channels for montelukast APIs.
- Development of combination therapies to enhance market offerings.
- Investment in R&D for novel formulations targeting pediatric patients.

By 2035, the montelukast API market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Application: Asthma (Largest) vs. Allergic Rhinitis (Fastest-Growing)

The market share distribution for the application segment of the GCC montelukast api market reveals that Asthma treatments dominate the landscape, reflecting a significant demand due to the high prevalence of asthma in the region. Allergic Rhinitis follows as a substantial segment, and while it holds a smaller share, it is growing rapidly as awareness and diagnosis improve, indicating a robust potential for further market expansion.

Growth trends in the application segment are driven by increasing healthcare access and the rising incidence of chronic respiratory ailments. Asthma remains a major focus, leveraging advancements in treatment innovations and healthcare initiatives. Conversely, the Emerging Allergic Rhinitis segment is benefiting from enhanced patient education and changing lifestyle factors, propelling it as the fastest-growing segment in this market.

Asthma (Dominant) vs. Allergic Rhinitis (Emerging)

Asthma treatments are the dominant force in the GCC montelukast api market, characterized by their widespread prescription and usage in addressing severe respiratory issues. The market for asthma management is continually evolving with new therapeutic options and combinations emerging to improve patient outcomes. On the other hand, Allergic Rhinitis is recognized as an emerging segment, experiencing accelerated growth due to rising awareness and lifestyle changes leading to increased incidences. This shift has prompted pharmaceutical companies to focus on developing specialized formulations, ensuring accessibility and efficacy. Both segments reflect ongoing innovations and a robust understanding of patient needs, positioning them strategically in the evolving healthcare landscape.

## Competitive Benchmarking

The montelukast API market exhibits a dynamic competitive landscape characterized by a blend of established players and emerging companies. Key growth drivers include the increasing prevalence of asthma and allergic rhinitis, alongside a rising demand for cost-effective therapeutic options. Major companies such as Merck & Co (US), Teva Pharmaceutical Industries (IL), and Cipla (IN) are strategically positioned to leverage their extensive research capabilities and established distribution networks. Merck & Co (US) focuses on innovation and product differentiation, while Teva Pharmaceutical Industries (IL) emphasizes cost leadership through efficient manufacturing processes. Cipla (IN) is actively pursuing regional expansion, particularly in the GCC, to enhance its market presence. Collectively, these strategies contribute to a competitive environment that is both collaborative and competitive, as companies seek to balance innovation with cost efficiency.Key business tactics in the montelukast API market include localizing manufacturing and optimizing supply chains to enhance responsiveness to market demands. The market structure appears moderately fragmented, with several key players holding substantial market shares. This fragmentation allows for a diverse range of products and pricing strategies, fostering competition among the major players. The collective influence of these companies shapes market dynamics, as they navigate regulatory challenges and strive for operational excellence.

In October  Merck & Co (US) announced a strategic partnership with a regional distributor to enhance its supply chain capabilities in the GCC. This move is significant as it aims to streamline distribution processes and improve access to montelukast API products, thereby positioning Merck to better meet the growing demand in the region. Such partnerships are likely to enhance operational efficiency and market penetration.

In September  Teva Pharmaceutical Industries (IL) launched a new manufacturing facility in the GCC, aimed at increasing its production capacity for montelukast API. This facility is expected to bolster Teva's ability to meet local demand while reducing lead times. The strategic importance of this investment lies in its potential to enhance Teva's competitive edge through localized production, which may lead to cost savings and improved supply chain reliability.

In August  Cipla (IN) expanded its product portfolio by introducing a new formulation of montelukast API tailored for pediatric patients. This strategic move reflects Cipla's commitment to addressing specific market needs and enhancing patient compliance. By diversifying its offerings, Cipla positions itself to capture a larger share of the market, particularly among families seeking effective treatments for children.

As of November  current competitive trends in the montelukast API market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex regulatory environments and enhancing innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift underscores the importance of agility and responsiveness in meeting the evolving needs of healthcare providers and patients.

## Recent News & Developments

Recent developments in the GCC Montelukast Active Pharmaceutical Ingredient (API) Market have shown significant growth, with key players like Teva Pharmaceutical Industries, Hikma Pharmaceuticals, and Merck expanding their operations. In September 2023, Hikma Pharmaceuticals secured approval for a new Montelukast formulation which is expected to increase market penetration in the GCC region. Meanwhile, Amgen and Lupin Pharmaceuticals are enhancing their presence through collaborations and partnerships aimed at improving accessibility to Montelukast in local markets.

In July 2023, Fresenius Kabi announced its plan to increase manufacturing capacity for Montelukast API, responding to rising demand.Over the past two years, the GCC market has witnessed steady growth, bolstered by the increasing prevalence of asthma and allergic rhinitis, driving demand for Montelukast. Additionally, in early 2022, Zydus Cadila announced a strategic partnership with local distributors to enhance its market share in GCC countries. However, no significant mergers and acquisitions involving the specified companies have been reported recently.

Overall, the market continues to evolve with strong contributions from various players, reflecting an optimistic outlook driven by healthcare reforms and regulatory support across the GCC.

## Report Scope

| MARKET SIZE 2024 | 38.88(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 42.99(USD Million) |
| MARKET SIZE 2035 | 117.25(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.55% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Merck & Co (US), Teva Pharmaceutical Industries (IL), Mylan N.V. (US), Sandoz (CH), Aurobindo Pharma (IN), Cipla (IN), Hikma Pharmaceuticals (GB), Zydus Cadila (IN), Sun Pharmaceutical Industries (IN) |
| Segments Covered | Application |
| Key Market Opportunities | Growing demand for montelukast API driven by increasing respiratory disorders and regulatory support for generic formulations. |
| Key Market Dynamics | Rising demand for montelukast APIs driven by regulatory support and increasing prevalence of respiratory disorders in the region. |
| Countries Covered | GCC |

## Frequently Asked Questions

**Q: What was the overall market valuation of the GCC montelukast API market in 2024?**
A: The overall market valuation was $38.88 Million in 2024.

**Q: What is the projected market valuation for the GCC montelukast API market by 2035?**
A: The projected valuation for 2035 is $117.25 Million.

**Q: What is the expected CAGR for the GCC montelukast API market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 10.55%.

**Q: Which companies are considered key players in the GCC montelukast API market?**
A: Key players include Merck & Co, Teva Pharmaceutical Industries, Mylan N.V., Sandoz, Aurobindo Pharma, Cipla, Hikma Pharmaceuticals, Zydus Cadila, and Sun Pharmaceutical Industries.

**Q: What segment had the highest valuation in the GCC montelukast API market in 2024?**
A: The Asthma segment had the highest valuation, ranging from $10.0 Million to $30.0 Million.

**Q: What is the valuation range for the Allergic Rhinitis segment in the GCC montelukast API market?**
A: The valuation range for the Allergic Rhinitis segment is between $8.0 Million and $24.0 Million.

**Q: How does the Bronchospasm segment perform in terms of valuation in the GCC montelukast API market?**
A: The Bronchospasm segment had a valuation range of $6.0 Million to $18.0 Million.

**Q: What is the valuation range for the Urticaria segment in the GCC montelukast API market?**
A: The Urticaria segment's valuation ranges from $4.0 Million to $12.0 Million.

**Q: What is the projected growth trend for the Others segment in the GCC montelukast API market?**
A: The Others segment is projected to have a valuation range from $10.88 Million to $33.25 Million.

**Q: How do the market dynamics appear for the GCC montelukast API market in the coming years?**
A: The market dynamics suggest a robust growth trajectory, with a projected valuation increase to $117.25 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/gcc-montelukast-api-market-53094*